|12 Months Ended|
Sep. 30, 2019
9. FDA REFUND
On August 29, 2018, the Company received notification from the Food and Drug Administration ("FDA") that the Company was being refunded $818,343 of 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA's review of the associated applications. The Company recorded the $818,343 receivable as other income during the year ended September 30, 2018 and received the refund on October 1, 2018.
The entire disclosure for financing receivable.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef